尼波卡利马布:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
尼波卡利马布 (Nipocalimab) 是一种新型单克隆抗体,目前已在美国获批用于一般化骨髓灰质炎. 它向新生儿碎片结晶 (Fc) 受体 (FcRn),以降低患者的IgG水平.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 尼波卡利马布是一种全人类单克隆抗体,向新生儿碎片结晶 (Fc) 受体 (FcRn).
- FcRn阻塞降低了循环免疫球蛋白G (IgG) 水平,这是自身免疫性疾病的关键机制.
- 自身免疫性疾病,如一般化肌痛性肌痛性肌痛症 (gMG),具有致病性自身抗体的特征.
研究的目的:
- 总结一下尼波卡利马布的发展里程碑.
- 为了突出尼波卡利马布首次获得监管批准,用于一般化骨髓灰质炎.
主要方法:
- 对尼波卡利马布的临床前和临床发展数据的审查.
- 对监管提交和批准流程的分析.
主要成果:
- 尼波卡利马布在2025年4月29日获得了美国FDA的首次批准.
- 批准适用于患有抗乙胆受体或抗肌肉特异性氨酸激酶抗体阳性全般化肌痛严重症的成人和儿科患者 (≥12岁).
- 日本和欧盟正在对gMG进行监管审查.
结论:
- 尼波卡利马布在治疗gMG方面取得了重大进展.
- FcRn抑制机制为自身免疫性疾病提供了有针对性的方法.
- 成功开发和批准为在自身免疫性疾病中更广泛应用铺平了道路.
更多相关视频
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
FDA Approved Drugs: Changes to Approved Drugs
Therapeutic Drug Monitoring: Overview and Classification
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
